Nitto Avecia was the first CMO to serve the oligonucleotide therapeutic market. Since then, we have manufactured more than 1,200 oligonucleotide sequences and developed the most extensive late-phase portfolio of any oligonucleotide CMO. This experience gives our analytical, manufacturing, and quality teams unparalleled expertise to make your oligonucleotide program a success.
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.